EGFR and non-small cell lung carcinoma: The monoclonal antibody inhibitor of epidermal growth factor receptor (EGFR)- cetuximab adds modest benefit to front-line chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC)[1,2].